ROS1基因重排与诊断前后血栓栓塞事件风险升高相关
本研究旨在明确晚期ROS1基因重排非小细胞肺癌(ROS1+ NSCLC)血栓栓塞事件(TEE)发生率是否高于预期,纳入美国和中国五家学术中心的ROS1+、ALK+、EGFR+和KRAS+晚期NSCLC患者,比较诊断±90天内TEE发生率。结果显示ROS1+患者TEE风险显著高于EGFR+和KRAS+,与ALK+相比数值上较高但无统计学差异,总生存无显著差异。
要点
- ROS1+晚期NSCLC诊断±90天内TEE发生率为34.7%(33例),高于EGFR+的13.7%和KRAS+的18.4%。
- 多因素分析中ROS1+较EGFR+的TEE比值比为2.44(95%CI 1.31-4.57,p=0.005)。
- ROS1+较KRAS+的TEE比值比为2.62(95%CI 1.26-5.46,p=0.01),较ALK+无统计学显著差异。
核心结论
- 晚期ROS1+ NSCLC患者诊断前后TEE风险显著高于EGFR+和KRAS+患者。
- ALK+ NSCLC患者的TEE风险可能同样升高。
研究设计与样本
- 研究纳入美国和中国五家学术中心2002年10月至2018年4月诊断的ROS1+、ALK+、EGFR+或KRAS+晚期NSCLC患者,采集诊断±365天内静脉和动脉TEE。
- 主要终点为诊断±90天内ROS1+相较ALK+、EGFR+和KRAS+的TEE发生率,采用逻辑回归评估不同驱动基因间TEE比值比差异。
- 可分析数据包括95例ROS1+、193例ALK+、300例EGFR+和152例KRAS+患者。
主要发现
- TEE发生率分别为ROS1+ 34.7%(n=33)、ALK+ 22.3%(n=43)、EGFR+ 13.7%(n=41)、KRAS+ 18.4%(n=28)。
- 单因素分析中ROS1+的TEE比值比高于ALK+、EGFR+和KRAS+队列。
- 多因素分析中ROS1+较EGFR+的TEE比值比为2.44(95%CI 1.31-4.57,p=0.005)。
- 多因素分析中ROS1+较KRAS+的TEE比值比为2.62(95%CI 1.26-5.46,p=0.01)。
- ROS1+较ALK+的TEE比值比为1.45(p=0.229),未达统计学显著。
关键数值与推荐
- 主要终点为诊断±90天内TEE发生率。
- TEE采集窗口为诊断±365天内。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study aims to determine whether advanced ROS1 gene-rearranged NSCLC (ROS1+ NSCLC) has a higher than expected thromboembolic event (TEE) rate. METHODS: Venous and arterial TEEs within ±365 days of diagnosis of ROS1+, ALK+, EGFR+, or KRAS+ advanced NSCLC at five academic centers in the United States and China were captured (October 2002-April 2018). The primary endpoint was incidence of TEE in ROS1+ compared to anaplastic lymphoma kinase (ALK)+, EGFR+, and KRAS+ NSCLC within ±90 days of diagnosis. Logistic regression was used to assess if the odds of TEE differed among oncogene drivers. RESULTS: Eligible data from 95 ROS1+, 193 ALK+, 300 EGFR+, and 152 KRAS+ NSCLC patients were analyzed. The incidence rate of TEE was 34.7% (n = 33), 22.3% (n = 43), 13.7% (n = 41), and 18.4% (n = 28), respectively. In univariate analysis, the odds of a TEE in ROS1+ NSCLC were higher than ALK+, EGFR+, and KRAS+ cohorts. In multivariable analysis, the odds of a TEE were significantly higher for ROS1+ compared to EGFR+ and KRAS+ cohorts, the odds ratio (OR) was 2.44, with a 95% confidence interval of 1.31-4.57 (p = 0.005), and OR: 2.62, with a 95% confidence interval of 1.26-5.46 (p = 0.01), respectively. Although numerically superior, the odds for a TEE with ROS1+ compared to ALK+ was not statistically significant (OR: 1.45, p = 0.229). Overall survival was not significantly different in patients with or without TEE within ±90 days of diagnosis in the overall study cohort or within each molecular group. CONCLUSIONS: The risk of peridiagnostic TEEs is significantly elevated in patients with advanced ROS+ NSCLC compared to EGFR+ and KRAS+ cases. TEE risk may be similarly elevated in ALK+ NSCLC.
引用
- Ng TL, Smith DE, Mushtaq R, et al. ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events. J Thorac Oncol. 2018. PMID: 30543838. doi:10.1016/j.jtho.2018.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。